Rein Therapeutics, Inc. (RNTX) has a large shareholder group led by Voss Capital reporting passive ownership on an amended Schedule 13G. As of the close of business on December 31, 2025, Voss Capital and related entities may be deemed to beneficially own 4,468,969 shares of Rein Therapeutics common stock, representing approximately 17.0% of the outstanding shares.
This percentage is based on 26,286,382 shares outstanding as of November 10, 2025, as disclosed in the company’s Form 10-Q. The filing is made on a passive basis, with the reporting persons certifying that the securities are not held for the purpose of changing or influencing control of Rein Therapeutics, apart from activities related to director nominations under the cited rule.
Positive
None.
Negative
None.
Insights
Voss Capital reports a sizable but passive 17% stake in Rein Therapeutics.
The filing shows Voss Capital and affiliated funds, including Voss Value Master Fund and Voss Value‑Oriented Special Situations Fund, may be deemed to beneficially own 4,468,969 shares, or about 17.0% of Rein Therapeutics’ common stock as of December 31, 2025.
Ownership is spread across funds and managed accounts, with Voss Advisors GP and Travis W. Cocke reported as control persons of these entities. The percentage is calculated using 26,286,382 shares outstanding as of November 10, 2025, from Rein’s Form 10‑Q.
The group files on Schedule 13G/A, accompanied by a certification that the holdings are not for the purpose of changing or influencing control, other than activities connected with a director nomination provision. Future company filings may clarify any changes in this ownership level or reporting status.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Rein Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
00887A204
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
00887A204
1
Names of Reporting Persons
Voss Value Master Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
926,441.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
926,441.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
926,441.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.5 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
00887A204
1
Names of Reporting Persons
Voss Value-Oriented Special Situations Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
500,000.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
500,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
00887A204
1
Names of Reporting Persons
Voss Advisors GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,426,441.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,426,441.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,426,441.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
00887A204
1
Names of Reporting Persons
Voss Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,776,484.00
6
Shared Voting Power
692,485.00
7
Sole Dispositive Power
3,776,484.00
8
Shared Dispositive Power
692,485.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,468,969.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
00887A204
1
Names of Reporting Persons
Cocke Travis W.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,776,484.00
6
Shared Voting Power
692,485.00
7
Sole Dispositive Power
3,776,484.00
8
Shared Dispositive Power
692,485.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,468,969.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Rein Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
Item 2.
(a)
Name of person filing:
The names of the persons filing this statement on Schedule 13G (collectively, the "Reporting Persons") are:
Voss Value Master Fund, L.P. ("Voss Value Master Fund");
Voss Value-Oriented Special Situations Fund, L.P. ("Voss Value-Oriented Special Situations Fund");
Voss Advisors GP, LLC ("Voss GP");
Voss Capital, L.P. ("Voss Capital"); and
Travis W. Cocke.
(b)
Address or principal business office or, if none, residence:
Voss Value Master Fund
3773 Richmond, Suite 850
Houston, Texas 77046
Voss Value-Oriented Special Situations Fund
3773 Richmond, Suite 850
Houston, Texas 77046
Voss GP
3773 Richmond, Suite 850
Houston, Texas 77046
Voss Capital
3773 Richmond, Suite 850
Houston, Texas 77046
Travis W. Cocke
3773 Richmond, Suite 850
Houston, Texas 77046
(c)
Citizenship:
Voss Value Master Fund
Cayman Islands
Voss Value-Oriented Special Situations Fund
Texas
Voss GP
Texas
Voss Capital
Texas
Travis W. Cocke
USA
(d)
Title of class of securities:
Common Stock, $0.001 par value
(e)
CUSIP No.:
00887A204
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on December 31, 2025:
(i) Voss Value Master Fund beneficially owned 926,441 shares of Common Stock, $0.001 par value, of the Issuer (the "Shares").
(ii) Voss Value-Oriented Special Situations Fund beneficially owned 500,000 Shares.
(iii) Voss GP, as the general partner of Voss Value Master Fund and Voss Value-Oriented Special Situations Fund, may be deemed the beneficial owner of the (i) 926,441 Shares beneficially owned by Voss Value Master Fund and (ii) 500,000 Shares beneficially owned by Voss Value-Oriented Special Situations Fund.
(iv) Voss Capital, as the investment manager of Voss Value Master Fund, Voss Value-Oriented Special Situations Fund and certain accounts managed by Voss Capital (the "Voss Managed Accounts"), may be deemed the beneficial owner of the (i) 926,441 Shares beneficially owned by Voss Value Master Fund, (ii) 500,000 Shares beneficially owned by Voss Value-Oriented Special Situations Fund and (iii) 3,042,528 Shares held in the Voss Managed Accounts.
(v) Mr. Cocke, as the managing member of each of Voss Capital and Voss GP, may be deemed the beneficial owner of the (i) 926,441 Shares owned by Voss Value Master Fund, (ii) 500,000 Shares beneficially owned by Voss Value-Oriented Special Situations Fund and (iii) 3,042,528 Shares held in the Voss Managed Accounts.
(b)
Percent of class:
The aggregate percentage of the Shares reported owned by each person named herein is based upon 26,286,382 Shares outstanding as of November 10, 2025, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2025.
As of the close of business on December 31, 2025:
(i) Voss Value Master Fund may be deemed to beneficially own approximately 3.5% of the outstanding Shares;
(ii) Voss Value-Oriented Special Situations Fund may be deemed to beneficially own approximately 1.9% of the outstanding Shares;
(iii) Voss GP may be deemed to beneficially own approximately 5.4% of the outstanding Shares;
(iv) Voss Capital may be deemed to beneficially own approximately 17.0% of the outstanding Shares (approximately 11.6% of the outstanding Shares are held in the Voss Managed Accounts); and
(v) Mr. Cocke may be deemed to beneficially own approximately 17.0% of the outstanding Shares.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on May 14, 2025.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Voss Value Master Fund, LP
Signature:
/s/ Travis W. Cocke
Name/Title:
Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner
Date:
02/13/2026
Voss Value-Oriented Special Situations Fund, LP
Signature:
/s/ Travis W. Cocke
Name/Title:
Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner
What stake in Rein Therapeutics (RNTX) does Voss Capital report on this Schedule 13G/A?
Voss Capital and related entities report beneficial ownership of about 4,468,969 Rein Therapeutics shares, or roughly 17.0% of the outstanding common stock. This reflects holdings across Voss funds and managed accounts as of December 31, 2025, based on 26,286,382 shares outstanding.
Which Voss entities are included as reporting persons for Rein Therapeutics (RNTX)?
Reporting persons include Voss Value Master Fund, Voss Value-Oriented Special Situations Fund, Voss Advisors GP, Voss Capital, and individual manager Travis W. Cocke. Each entity’s beneficial ownership is detailed, with Voss Capital and Cocke reported as control persons over the various funds and accounts.
How much of Rein Therapeutics (RNTX) does each Voss fund beneficially own?
Voss Value Master Fund beneficially owns 926,441 Rein Therapeutics shares, about 3.5% of the class. Voss Value-Oriented Special Situations Fund holds 500,000 shares, about 1.9%. These positions roll up to Voss Advisors GP and Voss Capital as control and investment manager entities.
How is the 17.0% ownership in Rein Therapeutics (RNTX) by Voss Capital calculated?
The 17.0% figure uses 26,286,382 Rein Therapeutics shares outstanding as of November 10, 2025, from the company’s Form 10-Q. Voss Capital’s beneficial ownership includes fund holdings plus 3,042,528 shares in managed accounts, totaling 4,468,969 shares as of December 31, 2025.
Is Voss Capital’s stake in Rein Therapeutics (RNTX) reported as passive or activist?
The stake is reported on a Schedule 13G/A with a certification that the securities were not acquired and are not held to change or influence control of Rein Therapeutics. The certification carves out only activities related to a director nomination rule reference in the statement.
Who signs the Rein Therapeutics (RNTX) Schedule 13G/A for the Voss group?
The filing is signed by Travis W. Cocke. He signs in various capacities, including as managing member of Voss Advisors GP, LLC, general partner of the funds, and as managing member or individual signatory where applicable, certifying the accuracy of the ownership information provided.
